TRANSIENT MRNA THERAPEUTICS FOR ACUTE ORGAN SUPPORT IN CRITICAL CARE: A NEW HOPE IN TRANSLATIONAL MEDICINE

The rapid evolution of messenger RNA (mRNA) technology has opened unprecedented avenues in modern pharmacology, extending far beyond prophylactic vaccines into the realm of acute therapeutic intervention. In the highly volatile environment of the intensive care unit (ICU), acute organ failure—such as acute kidney injury, hepatic failure, and acute respiratory distress syndrome—carries a persistently high mortality rate. Transient mRNA therapeutics offer a paradigm-shifting approach by temporarily reprogramming cellular machinery to produce therapeutic proteins, thereby providing acute organ support without the risks of permanent genomic alteration. However, deploying these potent biological agents in critically ill patients requires precise dynamic dosing and rigorous real-time monitoring to prevent adverse hyper-responses. This paper proposes a novel translational medicine framework that integrates hypothetical transient mRNA therapeutic regimens with advanced artificial intelligence, specifically reinforcement learning and time-series foundation models, to optimize individualized dosing strategies. By synthesizing current biological capabilities with state-of-the-art computational critical care techniques, we present an end-to-end conceptual pipeline for the adaptive administration of mRNA therapies. Through a rigorously structured discussion on methodological design, evaluation planning, and ethical deployment, this work aims to bridge the gap between molecular innovation and algorithmic clinical decision support, ultimately paving the way toward a new era of precision critical care medicine.信使核糖核酸（messenger RNA, mRNA）技术的飞速演进为现代药理学开辟了前所未有的发展路径，其应用范畴早已远超预防性疫苗领域，拓展至急性治疗干预的全新赛道。在重症监护病房（intensive care unit, ICU）瞬息万变的临床环境中，急性器官衰竭——如急性肾损伤、肝衰竭与急性呼吸窘迫综合征——始终伴随居高不下的死亡率。瞬时mRNA治疗药物通过暂时性重编程细胞机制以表达治疗性蛋白，为急性器官支持提供了范式革新的解决方案，且不会引发永久性基因组改变的风险。然而，在危重症患者体内应用这类强效生物制剂，需要精准的动态给药方案与严格的实时监测，以避免出现过激不良反应。本研究提出一种全新的转化医学框架，将假想的瞬时mRNA治疗方案与先进人工智能技术——尤其是强化学习与时序基础模型——相结合，以优化个体化给药策略。通过整合当前的生物学研究能力与前沿计算重症监护技术，我们构建了一套用于mRNA治疗自适应给药的端到端概念性流程。通过围绕方法学设计、评估规划与伦理部署展开严谨系统的论述，本研究旨在弥合分子创新与算法化临床决策支持之间的鸿沟，最终为精准重症监护医学的新纪元铺平道路。